Evidence map›Paper›PMID 40502583›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Activated Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells.

Raphael A Kirou, Iago Pinal-Fernandez, Maria Casal-Dominguez, Katherine Pak, Chiseko Ikenaga, Christopher Nelke, Sven Wischnewski, Stefania Del Orso, Faiza Naz, Shamima Islam and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Raphael A KirouMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-6481-4810
Iago Pinal-FernandezMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-6338-9218
Maria Casal-DominguezMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Katherine PakMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Chiseko IkenagaDepartment of Cell Biology and Anatomy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Christopher NelkeDepartment of Neurology, University Hospital Düsseldorf, Düsseldorf, Germany.
Sven WischnewskiDepartment of Neurology, Heidelberg University, Mannheim, Germany.
Stefania Del OrsoGenomic Technology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Faiza NazGenomic Technology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Shamima IslamGenomic Technology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Gustavo Gutierrez-CruzGenomic Technology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Thomas E LloydDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Lucas SchirmerDepartment of Neurology, Heidelberg University, Mannheim, Germany.
Tobias RuckDepartment of Neurology, University Hospital Düsseldorf, Düsseldorf, Germany.
Werner StenzelDepartment of Neurology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Berlin, Germany.
Albert Selva-O'CallaghanSystemic Autoimmune Disease Unit, Vall d'Hebron Institute of Research, Barcelona, Spain.
Jose C MilisendaMuscle Research Unit, Internal Medicine Department, Hospital Clinic, Barcelona, Spain.
Andrew L MammenMuscle Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inclusion body myositis (IBM) is an idiopathic inflammatory myopathy characterized by muscle-infiltrating KLRG1+ and TBX21+ cytotoxic T cells and type 1 inflammation. Myeloid dendritic cells (mDCs), including type 1 conventional dendritic (cDC1) cells, type 2 conventional dendritic (cDC2) cells, and mature immunoregulatory dendritic (mregDC) cells, have previously been reported in skeletal muscle of IBM patients and may activate these cytotoxic T cells. Here, we analyzed single-nucleus RNA-sequencing (snRNA-seq) and bulk RNA-sequencing (RNA-seq) data from skeletal muscle of IBM, other myositis, and control patients to identify and quantify these mDC subsets and characterize their contribution to IBM inflammation. Our findings reveal that all three mDC subsets are relatively increased and activated in muscle of IBM patients and correlate with IBM-specific inflammatory markers. Our data specifically implicates cDC1 cells in CD8+ T cell activation via specific expression of both KLRG1 ligands,

Indexed as

Dendritic CellsInclusion Body MyositisMyositisType I Inflammation

Identifiers

PMID40502583
PMCPMC12155022

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.